An interventional study of Sphenopalatine Ganglion Acupuncture and Mometasone furoate nasal spray in Allergic Rhinitis, sponsored by Zhongshan Torch Development Zone People's Hospital. Not yet recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-08-28.
Sponsored by Zhongshan Torch Development Zone People's Hospital · Not applicable, Interventional, and Treatment
Allergic rhinitis can cause sneezing, a runny or blocked nose, and nasal itching, which may affect daily activities and quality of life. Nasal corticosteroid sprays are commonly used to control these symptoms, but some people may still have bothersome symptoms.
The purpose of this study is to find out whether adding sphenopalatine ganglion acupuncture to mometasone furoate nasal spray can improve allergic rhinitis symptoms more than using the nasal spray alone, and to evaluate the safety of this treatment.
Adults with moderate-to-severe perennial allergic rhinitis will be randomly assigned to one of two treatment groups. Both groups will use mometasone furoate nasal spray for 4 weeks. Participants in one group will also receive sphenopalatine ganglion acupuncture twice a week for 4 weeks. Researchers will compare changes in nasal symptoms, quality of life, use of rescue medication, clinical examination findings, and adverse events between the two groups. Participants will also be followed after treatment to assess whether the treatment effects are maintained.
717 studies on the registry are indexed under Rhinitis, Allergic; 94 are open to participants now.
This study's planned enrollment of 150 is above the median of 68 across 552 interventional studies indexed under Rhinitis, Allergic.
Browse Rhinitis, Allergic studies →This is the only study on the registry with Zhongshan Torch Development Zone People's Hospital as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of allergic rhinitis according to the Chinese Guidelines for Diagnosis and Treatment of Allergic Rhinitis (2022 Revision), meeting all of the following criteria:
Presence of acute upper respiratory tract infection, acute or chronic rhinosinusitis, nasal polyps, severe nasal septal deviation, rhinitis medicamentosa, vasomotor rhinitis, infectious rhinitis, or other forms of non-allergic rhinitis.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to this group will receive intranasal corticosteroid treatment alone for 4 weeks.
Drug: Mometasone furoate nasal spray
Participants assigned to this group will receive sphenopalatine ganglion acupuncture alone for 4 weeks.
Procedure: Sphenopalatine Ganglion Acupuncture
Participants assigned to this group will receive sphenopalatine ganglion acupuncture combined with intranasal corticosteroid treatment for 4 weeks.
Procedure: Sphenopalatine Ganglion Acupuncture · Drug: Mometasone furoate nasal spray
Sphenopalatine ganglion acupuncture will be performed twice weekly for 4 consecutive weeks, for a total of 8 treatment sessions. Acupuncture will be performed alternately on the left and right sides without needle retention.
Also known as: Pterygopalatine Ganglion Acupuncture
Mometasone furoate nasal spray will be administered as two sprays into each nostril once daily for 4 consecutive weeks.
Also known as: Intranasal Corticosteroid
Change From Baseline in Total Nasal Symptom Score
Time frame: Baseline, Week 2, Week 4, Week 8 and Month 6.
Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire Score
Time frame: Baseline, Week 2, Week 4, Week 8 and Month 6
Total Non-Nasal Symptom Score
Time frame: Baseline, Week 2, Week 4, Week 8 and Month 6.
Change From Baseline in Nasal Examination Score
Time frame: Baseline and Week 4.
Number of Days of Rescue Medication Use
The total number of calendar days on which each participant uses at least one dose of protocol-permitted rescue medication during the 4-week treatment period will be recorded.
Time frame: During the 4-week treatment period
Change From Baseline in Peripheral Blood Eosinophil Count
Peripheral blood eosinophil count will be measured at baseline and Week 4. Change from baseline will be calculated as the Week 4 value minus the baseline value.
Time frame: Baseline and Week 4
Incidence of Treatment-Emergent Adverse Events
The number and proportion of participants experiencing adverse events during the study will be recorded. Acupuncture-related adverse events may include local pain, subcutaneous bleeding or hematoma, dizziness or fainting during acupuncture, needle-related complications, discomfort during mouth opening or chewing, gingival or maxillary discomfort, epistaxis, and local infection. Drug-related adverse events may include nasal dryness, epistaxis, throat discomfort, dry mouth, dizziness, rash, and other allergic reactions. The severity, management, outcome, and relationship of each adverse event to the study intervention will be assessed.
Time frame: From randomization through the end of study follow-up, up to 6 months
Plan to share: Yes — Deidentified individual participant data underlying the results reported in the published article.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 3-5 years
Access criteria: Data may be made available to qualified researchers upon reasonable request for scientifically sound research purposes, subject to approval by the principal investigator and the participating institution, and in accordance with applicable ethical and data protection requirements.
No publications or documents are linked to this record.
Start is estimated for Aug 2026; primary completion for Dec 2026, 4 months later.
Of 66 non-industry interventional studies with no phase under Rhinitis, Allergic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 28. This study's planned 4 months is below that.
Counting every sponsor, half of 87 studies reached it within 11 months; a quarter within 4 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mometasone Furoate